rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Samuel Joseph Parisi

VP, Finance (Interim PAO)

Company insider

Files Form 4 as: VP, Finance (Interim PAO), Alkermes.

Every Form 4 they filed

In numbers

Trades disclosed
72
Buys
0
Sells
6
Bought
$0
Sold
$2.1M
Companies
1
Companies where not an officer
0
First trade
18 Feb 2024
Last trade
29 May 2026
Last filed
29 May 2026

Companies traded

Where they are an officer
ALKS AlkermesOfficer · Pharmaceuticals · last 29 May 20260 buys · 6 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
30Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
29 May 2026filed 29 May 2026ALKS AlkermesPharmaceuticalsSEC FORM 4 Code M$68K3,392 at $20.03filing
29 May 2026filed 29 May 2026ALKS AlkermesPharmaceuticalsSEC FORM 4 Code M$248K12,825 at $19.34filing
29 May 2026filed 29 May 2026ALKS AlkermesPharmaceuticalsSEC FORM 4 Sold$687K16,217 at $42.36filing
29 May 2026filed 29 May 2026ALKS Alkermesoption or derivative · PharmaceuticalsSEC FORM 4 Code M—3,392 at $0.00filing
29 May 2026filed 29 May 2026ALKS Alkermesoption or derivative · PharmaceuticalsSEC FORM 4 Code M—12,825 at $0.00filing
29 May 2026filed 29 May 2026ALKS Alkermesoption or derivative · PharmaceuticalsSEC FORM 4 Code M—3,392 at $0.00filing
29 May 2026filed 29 May 2026ALKS Alkermesoption or derivative · PharmaceuticalsSEC FORM 4 Code M—12,825 at $0.00filing
29 May 2026filed 29 May 2026ALKS AlkermesPharmaceuticalsSEC FORM 4 Code M$68K3,392 at $20.03filing
29 May 2026filed 29 May 2026ALKS AlkermesPharmaceuticalsSEC FORM 4 Code M$248K12,825 at $19.34filing
29 May 2026filed 29 May 2026ALKS AlkermesPharmaceuticalsSEC FORM 4 Sold$687K16,217 at $42.36filing
2 Mar 2026filed 4 Mar 2026ALKS AlkermesPharmaceuticalsSEC FORM 4 Sold$202K6,890 at $29.29filing
2 Mar 2026filed 4 Mar 2026ALKS Alkermesoption or derivative · PharmaceuticalsSEC FORM 4 Code A—15,033 at $0.00filing
2 Mar 2026filed 4 Mar 2026ALKS Alkermesoption or derivative · PharmaceuticalsSEC FORM 4 Code A—14,176 at $0.00filing
2 Mar 2026filed 4 Mar 2026ALKS Alkermesoption or derivative · PharmaceuticalsSEC FORM 4 Code A—15,033 at $0.00filing
2 Mar 2026filed 4 Mar 2026ALKS Alkermesoption or derivative · PharmaceuticalsSEC FORM 4 Code A—14,176 at $0.00filing
2 Mar 2026filed 4 Mar 2026ALKS AlkermesPharmaceuticalsSEC FORM 4 Sold$202K6,890 at $29.29filing
26 Feb 2026filed 27 Feb 2026ALKS AlkermesPharmaceuticalsSEC FORM 4 Code M—2,747filing
26 Feb 2026filed 27 Feb 2026ALKS AlkermesPharmaceuticalsSEC FORM 4 Code F$25K808 at $30.73filing
26 Feb 2026filed 27 Feb 2026ALKS Alkermesoption or derivative · PharmaceuticalsSEC FORM 4 Code M—2,747filing
26 Feb 2026filed 27 Feb 2026ALKS Alkermesoption or derivative · PharmaceuticalsSEC FORM 4 Code M—2,747filing

Sectors

Health Care6

Buys in green, sells in red, by the company’s sector.

Related people

Anne Clem WhitakerDirector · Director at Alkermes plc, filing Form 4 there in the last year
Joshua ReedSVP, Chief Financial Officer · SVP, Chief Financial Officer at Alkermes plc, filing Form 4 there in the last year
David Joseph GaffinEVP, CLO, Alkermes, Inc. · EVP, CLO, Alkermes, Inc. at Alkermes plc, filing Form 4 there in the last year
Craig C. HopkinsonEVP R&D, Chief Medical Officer · EVP R&D, Chief Medical Officer at Alkermes plc, filing Form 4 there in the last year
Christian Todd NicholsSVP, Chief Commercial Officer · SVP, Chief Commercial Officer at Alkermes plc, filing Form 4 there in the last year
Gilbert Ray Cisneros, Jr.Representative, CA-31 · Also traded ALKS in the last 90 days
nancy lynn snydermanDirector · Also traded ALKS in the last 90 days
Donald J. TrumpPresident · Also traded ALKS in the last 90 days